Part the Cloud Translational Research for Alzheimer’s Disease Program: Enable the Molecule for Artificial Intelligence-Discovered Programs (PTC-EM-AI) Funding Program
PTC-EM-AI Funding Program supports researchers advancing AI-discovered therapies through lead optimization and IND-enabling work to develop disease-modifying treatments for Alzheimer’s and related dementias.
Browse similar grants
Funder: Alzheimer's Association
Due Dates: October 20, 2026 (LOI) | October 22, 2026 (ISTAART LOI) | December 15, 2026 (Application) | December 17, 2026 (ISTAART application)
Funding Amounts: Up to $1,000,000 per award, including direct and indirect costs, for two to three years
Summary: Supports experimental advancement of AI-discovered therapies for Alzheimer’s disease and related dementias through lead optimization and IND-enabling work.
Key Information: Applicants must hold a full-time Assistant Professor-equivalent or higher position; an approved current-cycle LOI is required.
Description
The Alzheimer’s Association’s Part the Cloud Enable the Molecule for Artificial Intelligence-Discovered Programs (PTC-EM-AI) bridges AI-driven therapeutic discovery and the experimental work needed to produce development-ready candidates for Alzheimer’s disease and related dementias. It prioritizes specific therapeutic programs where AI or machine learning was central to target identification, lead generation, selection, or optimization, supported by verifiable records and a milestone-driven experimental plan.
Two tracks support late hit-to-lead or completed hit-to-lead optimization and preparation for an investigational new drug (IND), or international equivalent, submission. Supported work includes medicinal chemistry or biologics engineering, pharmacology, ADME, PK/PD, brain exposure, biomarkers, safety assessment, formulation, and IND-enabling toxicology, manufacturing, and regulatory preparation. All therapeutic modalities are considered, including small molecules, PROTACs, antibodies, antisense oligonucleotides, gene therapies, and novel biologics. Only approaches with disease-modifying potential qualify.
